No Data
No Data
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $34
Optimistic Buy Rating for RegenXBio Driven by Promising RGX-202 Developments in DMD Treatment
Analysts Are Neutral on These Healthcare Stocks: Medtronic (MDT), RegenXBio (RGNX)
Regenxbio's DMD Gene Therapy Drives 122.3% Biomarker Uptick in Three-year-old